vs
雅培（ABT）与Aclaris Therapeutics, Inc.（ACRS）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是Aclaris Therapeutics, Inc.的8848.6倍（$11.5B vs $1.3M）。雅培净利率更高（15.5% vs -1528.6%，领先1544.1%）。雅培同比增速更快（4.4% vs -85.9%）。雅培自由现金流更多（$2.6B vs $-13.2M）。过去两年雅培的营收复合增速更高（7.2% vs -26.5%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
ABT vs ACRS — 直观对比
营收规模更大
ABT
是对方的8848.6倍
$1.3M
营收增速更快
ABT
高出90.4%
-85.9%
净利率更高
ABT
高出1544.1%
-1528.6%
自由现金流更多
ABT
多$2.6B
$-13.2M
两年增速更快
ABT
近两年复合增速
-26.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $1.3M |
| 净利润 | $1.8B | $-19.8M |
| 毛利率 | 57.0% | 58.9% |
| 营业利润率 | 19.6% | -1755.5% |
| 净利率 | 15.5% | -1528.6% |
| 营收同比 | 4.4% | -85.9% |
| 净利润同比 | -80.8% | 79.5% |
| 每股收益（稀释后） | $1.01 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTACRS
| Q4 25 | $11.5B | $1.3M | ||
| Q3 25 | $11.4B | $3.3M | ||
| Q2 25 | $11.1B | $1.8M | ||
| Q1 25 | $10.4B | $1.5M | ||
| Q4 24 | $11.0B | $9.2M | ||
| Q3 24 | $10.6B | $4.3M | ||
| Q2 24 | $10.4B | $2.8M | ||
| Q1 24 | $10.0B | $2.4M |
净利润ABTACRS
| Q4 25 | $1.8B | $-19.8M | ||
| Q3 25 | $1.6B | $-14.6M | ||
| Q2 25 | $1.8B | $-15.4M | ||
| Q1 25 | $1.3B | $-15.1M | ||
| Q4 24 | $9.2B | $-96.6M | ||
| Q3 24 | $1.6B | $-7.6M | ||
| Q2 24 | $1.3B | $-11.0M | ||
| Q1 24 | $1.2B | $-16.9M |
毛利率ABTACRS
| Q4 25 | 57.0% | 58.9% | ||
| Q3 25 | 55.4% | 83.7% | ||
| Q2 25 | 56.4% | 71.0% | ||
| Q1 25 | 56.9% | 65.2% | ||
| Q4 24 | 55.0% | 92.3% | ||
| Q3 24 | 55.8% | 85.0% | ||
| Q2 24 | 55.6% | 77.4% | ||
| Q1 24 | 55.2% | 66.3% |
营业利润率ABTACRS
| Q4 25 | 19.6% | -1755.5% | ||
| Q3 25 | 18.1% | -519.8% | ||
| Q2 25 | 18.4% | -1035.9% | ||
| Q1 25 | 16.3% | -1242.9% | ||
| Q4 24 | 17.4% | -1082.3% | ||
| Q3 24 | 17.5% | -240.9% | ||
| Q2 24 | 16.1% | -464.7% | ||
| Q1 24 | 13.9% | -789.4% |
净利率ABTACRS
| Q4 25 | 15.5% | -1528.6% | ||
| Q3 25 | 14.5% | -443.0% | ||
| Q2 25 | 16.0% | -868.3% | ||
| Q1 25 | 12.8% | -1036.8% | ||
| Q4 24 | 84.1% | -1048.3% | ||
| Q3 24 | 15.5% | -174.6% | ||
| Q2 24 | 12.5% | -397.2% | ||
| Q1 24 | 12.3% | -706.5% |
每股收益（稀释后）ABTACRS
| Q4 25 | $1.01 | $-0.16 | ||
| Q3 25 | $0.94 | $-0.12 | ||
| Q2 25 | $1.01 | $-0.13 | ||
| Q1 25 | $0.76 | $-0.12 | ||
| Q4 24 | $5.26 | $-1.21 | ||
| Q3 24 | $0.94 | $-0.11 | ||
| Q2 24 | $0.74 | $-0.15 | ||
| Q1 24 | $0.70 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $20.0M |
| 总债务越低越好 | $12.9B | — |
| 股东权益账面价值 | $52.1B | $103.1M |
| 总资产 | $86.7B | $160.5M |
| 负债/权益比越低杠杆越低 | 0.25× | — |
8季度趋势，按日历期对齐
现金及短期投资ABTACRS
| Q4 25 | $8.9B | $20.0M | ||
| Q3 25 | $7.7B | $25.3M | ||
| Q2 25 | $7.3B | $25.4M | ||
| Q1 25 | $6.8B | $30.4M | ||
| Q4 24 | $8.0B | $24.6M | ||
| Q3 24 | $7.8B | $47.7M | ||
| Q2 24 | $7.2B | $22.8M | ||
| Q1 24 | $6.7B | $35.8M |
总债务ABTACRS
| Q4 25 | $12.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABTACRS
| Q4 25 | $52.1B | $103.1M | ||
| Q3 25 | $51.0B | $120.1M | ||
| Q2 25 | $50.6B | $131.7M | ||
| Q1 25 | $48.8B | $144.1M | ||
| Q4 24 | $47.7B | $155.6M | ||
| Q3 24 | $39.8B | $130.2M | ||
| Q2 24 | $39.3B | $133.8M | ||
| Q1 24 | $38.8B | $142.0M |
总资产ABTACRS
| Q4 25 | $86.7B | $160.5M | ||
| Q3 25 | $84.2B | $175.5M | ||
| Q2 25 | $84.0B | $189.1M | ||
| Q1 25 | $81.4B | $198.1M | ||
| Q4 24 | $81.4B | $220.3M | ||
| Q3 24 | $74.4B | $182.4M | ||
| Q2 24 | $73.0B | $161.1M | ||
| Q1 24 | $72.5B | $174.1M |
负债/权益比ABTACRS
| Q4 25 | 0.25× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $-13.1M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $-13.2M |
| 自由现金流率自由现金流/营收 | 22.9% | -1015.8% |
| 资本支出强度资本支出/营收 | 6.0% | 1.9% |
| 现金转化率经营现金流/净利润 | 1.87× | — |
| 过去12个月自由现金流最近4个季度 | $7.4B | $-47.2M |
8季度趋势，按日历期对齐
经营现金流ABTACRS
| Q4 25 | $3.3B | $-13.1M | ||
| Q3 25 | $2.8B | $-10.9M | ||
| Q2 25 | $2.0B | $-10.0M | ||
| Q1 25 | $1.4B | $-13.1M | ||
| Q4 24 | $2.9B | $-8.9M | ||
| Q3 24 | $2.7B | $22.0M | ||
| Q2 24 | $2.0B | $-12.3M | ||
| Q1 24 | $1.0B | $-20.8M |
自由现金流ABTACRS
| Q4 25 | $2.6B | $-13.2M | ||
| Q3 25 | $2.3B | $-11.0M | ||
| Q2 25 | $1.5B | $-10.0M | ||
| Q1 25 | $933.0M | $-13.1M | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $1.4B | $-12.3M | ||
| Q1 24 | $627.0M | $-20.9M |
自由现金流率ABTACRS
| Q4 25 | 22.9% | -1015.8% | ||
| Q3 25 | 20.2% | -332.1% | ||
| Q2 25 | 13.9% | -563.5% | ||
| Q1 25 | 9.0% | -900.3% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 13.8% | -446.0% | ||
| Q1 24 | 6.3% | -873.6% |
资本支出强度ABTACRS
| Q4 25 | 6.0% | 1.9% | ||
| Q3 25 | 4.4% | 0.7% | ||
| Q2 25 | 4.5% | 1.2% | ||
| Q1 25 | 4.7% | 3.0% | ||
| Q4 24 | 6.6% | 0.0% | ||
| Q3 24 | 5.2% | 0.0% | ||
| Q2 24 | 5.1% | 0.5% | ||
| Q1 24 | 4.0% | 5.6% |
现金转化率ABTACRS
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
